RedHill Biopharma (RDHL) Cash from Operations: 2012-2022
Historic Cash from Operations for RedHill Biopharma (RDHL) over the last 11 years, with Dec 2022 value amounting to -$2.4 million.
- RedHill Biopharma's Cash from Operations rose 83.71% to -$2.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$29.2 million, marking a year-over-year increase of 55.13%. This contributed to the annual value of -$9.4 million for FY2024, which is 73.84% up from last year.
- Per RedHill Biopharma's latest filing, its Cash from Operations stood at -$2.4 million for Q4 2022, which was up 59.84% from -$6.0 million recorded in Q3 2022.
- Over the past 5 years, RedHill Biopharma's Cash from Operations peaked at -$2.4 million during Q4 2022, and registered a low of -$19.0 million during Q3 2021.
- Moreover, its 3-year median value for Cash from Operations was -$12.5 million (2020), whereas its average is -$11.8 million.
- In the last 5 years, RedHill Biopharma's Cash from Operations crashed by 107.45% in 2021 and then spiked by 83.71% in 2022.
- Quarterly analysis of 5 years shows RedHill Biopharma's Cash from Operations stood at -$8.2 million in 2018, then tumbled by 69.26% to -$13.9 million in 2019, then climbed by 8.39% to -$12.7 million in 2020, then declined by 16.95% to -$14.9 million in 2021, then soared by 83.71% to -$2.4 million in 2022.
- Its Cash from Operations stands at -$2.4 million for Q4 2022, versus -$6.0 million for Q3 2022 and -$16.6 million for Q2 2022.